title: Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma.
abstract: The etiologic relationship of the Epstein-Barr virus (EBV) to nasopharyngeal carcinoma prompted this study of the efficacy of interferon-gamma (IFN-gamma), which possesses antiviral and antitumor activity, in the treatment of recurrent carcinoma. Fourteen patients received recombinant IFN-gamma in daily intramuscular doses of 5-10 X 10(6) U/m2. Of 13 patients evaluable for response, five had a minor response; disease was stable in two and had progressed in six. EBV serology for immunoglobin (Ig) G, IgA-VCA, and early antigen was measured in six patients. In four of these, titers rose consistently with disease progression and in one patient, titers decreased with minor response.
authors.affiliation: Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: I W
authors.initials: IW
authors.lastname: Dimery
authors.forename: C
authors.initials: C
authors.lastname: Jacobs
authors.forename: A
authors.initials: A
authors.lastname: Tseng
authors.forename: S
authors.initials: S
authors.lastname: Saks
authors.forename: G
authors.initials: G
authors.lastname: Pearson
authors.forename: W K
authors.initials: WK
authors.lastname: Hong
authors.forename: J U
authors.initials: JU
authors.lastname: Gutterman
mesh_terms: D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D011994:Recombinant Proteins; D012008:Recurrence
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D011994:Recombinant Proteins; D007371:Interferon-gamma